Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study
To investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2021-12, Vol.182, p.109123-109123, Article 109123 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109123 |
|---|---|
| container_issue | |
| container_start_page | 109123 |
| container_title | Diabetes research and clinical practice |
| container_volume | 182 |
| creator | Ku, Eu Jeong Lee, Dong-Hwa Jeon, Hyun Jeong Oh, Tae Keun |
| description | To investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor.
A total of 362 patients with T2D were enrolled for this 3-year open-label, prospective observational study. Empagliflozin (25 mg/day, n = 185) or dapagliflozin (10 mg/day, n = 177) was added to the existing triple drug regimen. HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated.
At 3 years, changes in HbA1c and FPG were −1.7% (standard error [SE] 0.10) and −60.0 mg/dL(2.2), and −1.1%(0.12) and −48.1 mg/dL(3.6), for empagliflozin and dapagliflozin group, respectively (P = 0.001 and P = 0.055). Empagliflozin group showed significantly greater body weight reduction (-4.5 kg [SE 0.35] vs. −1.0 kg [SE 0.40], P = 0.024) and had beneficial effects on HDL cholesterol and LDL cholesterol (both P |
| doi_str_mv | 10.1016/j.diabres.2021.109123 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2594296740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822721004824</els_id><sourcerecordid>2594296740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-dcf27e8e57ee329991d8dcea30807198ee4c5d1a145f357fd7673f3266a3b24b3</originalsourceid><addsrcrecordid>eNqFUcuO1DAQtBCIHRY-AeQjlwx-JHHCBaEVL2kkLnC2HLu961Fe63YGhe_iA_FsBsQNyZKtVpWruoqQl5ztOeP1m-PeBdNFwL1ggudZy4V8RHa8UaJohFCPyS7jmof3FXmGeGSM1bKsnpIrWaqSqVLsyK_DNN4WCeJAwXuwKZxgBERqRkfReEgrnTy9X4yLy9wDtdPQhdGkMI003UE080p_hHRHYZjNbR98P_0MIz1BxAWpM_8O85kzE8aEGyetM1BBz5tAAnxLZbGCiXSOE86bGTp1CPH0IGh6imlx63PyxJse4cXlvibfP374dvO5OHz99OXm_aGwJRepcNYLBQ1UCkCKtm25a5wFI1nDFG8bgNJWjhteVl5WyjtVK-mlqGsjO1F28pq83v7Nfu4XwKSHgBb63owwLahF1ZairXOWGVptUJutYwSv5xgGE1fNmT4Xpo_6Upg-F6a3wjLv1UVi6QZwf1l_GsqAdxsA8qKnAFGjzQlacCHmhLSbwn8kfgML0a8D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2594296740</pqid></control><display><type>article</type><title>Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ku, Eu Jeong ; Lee, Dong-Hwa ; Jeon, Hyun Jeong ; Oh, Tae Keun</creator><creatorcontrib>Ku, Eu Jeong ; Lee, Dong-Hwa ; Jeon, Hyun Jeong ; Oh, Tae Keun</creatorcontrib><description>To investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor.
A total of 362 patients with T2D were enrolled for this 3-year open-label, prospective observational study. Empagliflozin (25 mg/day, n = 185) or dapagliflozin (10 mg/day, n = 177) was added to the existing triple drug regimen. HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated.
At 3 years, changes in HbA1c and FPG were −1.7% (standard error [SE] 0.10) and −60.0 mg/dL(2.2), and −1.1%(0.12) and −48.1 mg/dL(3.6), for empagliflozin and dapagliflozin group, respectively (P = 0.001 and P = 0.055). Empagliflozin group showed significantly greater body weight reduction (-4.5 kg [SE 0.35] vs. −1.0 kg [SE 0.40], P = 0.024) and had beneficial effects on HDL cholesterol and LDL cholesterol (both P < 0.05). The overall incidence of adverse events, cardiovascular events and mortality did not differ between the two groups.
Quadruple combination therapy with either empagliflozin or dapagliflozin showed a positive long-term effect in the glycemic control and body weight reduction with generally well tolerance. In general, the use of empagliflozin performed better than dapagliflozin.
Clinical Trial Number NCT03748810 (ClinicalTrials.gov).</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2021.109123</identifier><identifier>PMID: 34740742</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Benzhydryl Compounds ; Dapagliflozin ; Diabetes Mellitus, Type 2 - drug therapy ; Durability ; Empagliflozin ; Glucosides ; Humans ; Quadruple combination therapy ; SGLT2 inhibitor ; Type 2 Diabetes mellitus</subject><ispartof>Diabetes research and clinical practice, 2021-12, Vol.182, p.109123-109123, Article 109123</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-dcf27e8e57ee329991d8dcea30807198ee4c5d1a145f357fd7673f3266a3b24b3</citedby><cites>FETCH-LOGICAL-c412t-dcf27e8e57ee329991d8dcea30807198ee4c5d1a145f357fd7673f3266a3b24b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diabres.2021.109123$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34740742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ku, Eu Jeong</creatorcontrib><creatorcontrib>Lee, Dong-Hwa</creatorcontrib><creatorcontrib>Jeon, Hyun Jeong</creatorcontrib><creatorcontrib>Oh, Tae Keun</creatorcontrib><title>Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>To investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor.
A total of 362 patients with T2D were enrolled for this 3-year open-label, prospective observational study. Empagliflozin (25 mg/day, n = 185) or dapagliflozin (10 mg/day, n = 177) was added to the existing triple drug regimen. HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated.
At 3 years, changes in HbA1c and FPG were −1.7% (standard error [SE] 0.10) and −60.0 mg/dL(2.2), and −1.1%(0.12) and −48.1 mg/dL(3.6), for empagliflozin and dapagliflozin group, respectively (P = 0.001 and P = 0.055). Empagliflozin group showed significantly greater body weight reduction (-4.5 kg [SE 0.35] vs. −1.0 kg [SE 0.40], P = 0.024) and had beneficial effects on HDL cholesterol and LDL cholesterol (both P < 0.05). The overall incidence of adverse events, cardiovascular events and mortality did not differ between the two groups.
Quadruple combination therapy with either empagliflozin or dapagliflozin showed a positive long-term effect in the glycemic control and body weight reduction with generally well tolerance. In general, the use of empagliflozin performed better than dapagliflozin.
Clinical Trial Number NCT03748810 (ClinicalTrials.gov).</description><subject>Benzhydryl Compounds</subject><subject>Dapagliflozin</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Durability</subject><subject>Empagliflozin</subject><subject>Glucosides</subject><subject>Humans</subject><subject>Quadruple combination therapy</subject><subject>SGLT2 inhibitor</subject><subject>Type 2 Diabetes mellitus</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUcuO1DAQtBCIHRY-AeQjlwx-JHHCBaEVL2kkLnC2HLu961Fe63YGhe_iA_FsBsQNyZKtVpWruoqQl5ztOeP1m-PeBdNFwL1ggudZy4V8RHa8UaJohFCPyS7jmof3FXmGeGSM1bKsnpIrWaqSqVLsyK_DNN4WCeJAwXuwKZxgBERqRkfReEgrnTy9X4yLy9wDtdPQhdGkMI003UE080p_hHRHYZjNbR98P_0MIz1BxAWpM_8O85kzE8aEGyetM1BBz5tAAnxLZbGCiXSOE86bGTp1CPH0IGh6imlx63PyxJse4cXlvibfP374dvO5OHz99OXm_aGwJRepcNYLBQ1UCkCKtm25a5wFI1nDFG8bgNJWjhteVl5WyjtVK-mlqGsjO1F28pq83v7Nfu4XwKSHgBb63owwLahF1ZairXOWGVptUJutYwSv5xgGE1fNmT4Xpo_6Upg-F6a3wjLv1UVi6QZwf1l_GsqAdxsA8qKnAFGjzQlacCHmhLSbwn8kfgML0a8D</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Ku, Eu Jeong</creator><creator>Lee, Dong-Hwa</creator><creator>Jeon, Hyun Jeong</creator><creator>Oh, Tae Keun</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study</title><author>Ku, Eu Jeong ; Lee, Dong-Hwa ; Jeon, Hyun Jeong ; Oh, Tae Keun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-dcf27e8e57ee329991d8dcea30807198ee4c5d1a145f357fd7673f3266a3b24b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Benzhydryl Compounds</topic><topic>Dapagliflozin</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Durability</topic><topic>Empagliflozin</topic><topic>Glucosides</topic><topic>Humans</topic><topic>Quadruple combination therapy</topic><topic>SGLT2 inhibitor</topic><topic>Type 2 Diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ku, Eu Jeong</creatorcontrib><creatorcontrib>Lee, Dong-Hwa</creatorcontrib><creatorcontrib>Jeon, Hyun Jeong</creatorcontrib><creatorcontrib>Oh, Tae Keun</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ku, Eu Jeong</au><au>Lee, Dong-Hwa</au><au>Jeon, Hyun Jeong</au><au>Oh, Tae Keun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2021-12</date><risdate>2021</risdate><volume>182</volume><spage>109123</spage><epage>109123</epage><pages>109123-109123</pages><artnum>109123</artnum><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>To investigate the long-term effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor.
A total of 362 patients with T2D were enrolled for this 3-year open-label, prospective observational study. Empagliflozin (25 mg/day, n = 185) or dapagliflozin (10 mg/day, n = 177) was added to the existing triple drug regimen. HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated.
At 3 years, changes in HbA1c and FPG were −1.7% (standard error [SE] 0.10) and −60.0 mg/dL(2.2), and −1.1%(0.12) and −48.1 mg/dL(3.6), for empagliflozin and dapagliflozin group, respectively (P = 0.001 and P = 0.055). Empagliflozin group showed significantly greater body weight reduction (-4.5 kg [SE 0.35] vs. −1.0 kg [SE 0.40], P = 0.024) and had beneficial effects on HDL cholesterol and LDL cholesterol (both P < 0.05). The overall incidence of adverse events, cardiovascular events and mortality did not differ between the two groups.
Quadruple combination therapy with either empagliflozin or dapagliflozin showed a positive long-term effect in the glycemic control and body weight reduction with generally well tolerance. In general, the use of empagliflozin performed better than dapagliflozin.
Clinical Trial Number NCT03748810 (ClinicalTrials.gov).</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>34740742</pmid><doi>10.1016/j.diabres.2021.109123</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2021-12, Vol.182, p.109123-109123, Article 109123 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2594296740 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Benzhydryl Compounds Dapagliflozin Diabetes Mellitus, Type 2 - drug therapy Durability Empagliflozin Glucosides Humans Quadruple combination therapy SGLT2 inhibitor Type 2 Diabetes mellitus |
| title | Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T01%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20effectiveness%20and%20safety%20of%20quadruple%20combination%20therapy%20with%20empagliflozin%20versus%20dapagliflozin%20in%20patients%20with%20type%202%20diabetes:%203-year%20prospective%20observational%20study&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Ku,%20Eu%20Jeong&rft.date=2021-12&rft.volume=182&rft.spage=109123&rft.epage=109123&rft.pages=109123-109123&rft.artnum=109123&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2021.109123&rft_dat=%3Cproquest_cross%3E2594296740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2594296740&rft_id=info:pmid/34740742&rft_els_id=S0168822721004824&rfr_iscdi=true |